胃肠间质瘤个体化治疗策略的探讨

胃肠间质瘤（GIST）是最常见的胃肠道间叶源性肿瘤,多见于胃和小肠,GIST多具有恶性潜能,生物学行为可以从良性到高度恶性不等。GIST的预后与肿瘤的发病部位、瘤体大小、核分裂数以及肿瘤是否破裂密切相关,伊马替尼辅助治疗明显延长了GIST患者的生存时间。近年对于GIST患者实施个体化治疗的理念也得到了越来越多的重视,本文就GIST个体化治疗的策略研究进行阐述。

Individualized treatment strategy for gastrointestinal stromal tumor

Gastrointestinal stromal tumor (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, and are commonly located in the stomach and small intestine. All GIST have malignant potential, ranging from small lesions with a benign behavior to highly malignant sarcomas. The prognosis of gastrointestinal stromal tumor is closely related to the tumor location、tumor size、mitotic count and rupture of the tumors. Adjuvant therapy with imatinib has significantly prolonged the survival time of GIST patients. Recently, more and more attention has been paid to the concept of individualized treatment for gastrointestinal stromal tumor. And this article reviews the strategy of individualized treatment for gastrointestinal stromal tumor.